Key result
Compared with single antiplatelet therapy, 3-month and 6-month DAPT following TAVR increased major or life-threatening bleeding.
Why the study?
Although guidelines recommend DAPT for 3 to 6 months after TAVR, no studies had directly compared outcomes of different DAPT durations.
Does single antiplatelet therapy reduce bleeding without increasing stroke or death compared to 3- or 6-month dual antiplatelet therapy in patients following TAVR?
Meta-Analysis (n=2,498)
Does single antiplatelet therapy reduce bleeding without increasing stroke or death compared to 3- or 6-month dual antiplatelet therapy in patients following TAVR?
Single antiplatelet therapy with aspirin following TAVR is associated with lower bleeding risk without increasing stroke or death compared to 3- or 6-month DAPT.
Answers are grounded in this paper and cite their sources.
Supports single antiplatelet therapy after TAVR to reduce bleeding; challenges routine 3- or 6-month DAPT in guidelines.
Background Although current guidelines recommend dual antiplatelet therapy (DAPT) for 3 to 6 months following transcatheter aortic valve replacement (TAVR), there are no studies directly comparing outcomes of different durations of DAPT following TAVR. Methods and Results PubMed, EMBASE, and Cochrane Database were searched through November 2020 to identify clinical studies that investigated single antiplatelet therapy versus DAPT use following TAVR. Studies using oral anticoagulants and antiplatelet therapy concomitantly were excluded. The DAPT group was subdivided by the duration of DAPT. We extracted the risk ratios (RRs) of major or life‐threatening bleeding, stroke, and all‐cause mortality. Four randomized controlled trials, 2 propensity‐score matched studies, and 1 observational study were identified, yielding a total of 2498 patients who underwent TAVR assigned to the single antiplatelet therapy group (n=1249), 3‐month DAPT group (n=485), or 6‐month DAPT group (n=764). Pooled analyses demonstrated that when compared with the single antiplatelet therapy group, the rates of major or life‐threatening bleeding were significantly higher in the 3‐ and 6‐month DAPT groups (RR [95% CI]=2.13 [1.33–3.40], P =0.016; RR [95% CI]=2.54 [1.49–4.33], P =0.007, respectively) with no difference between the 3‐month DAPT versus 6‐month DAPT groups. The rates of stroke and all‐cause mortality were similar among the 3 groups. Conclusions In this network meta‐analysis of antiplatelet therapy following TAVR, single antiplatelet therapy with aspirin had lower bleeding without increasing stroke or death when compared with either 3‐ or 6‐month DAPT.
No takes yet. Share an insight, caveat, or question.
Kuno et al. (2021) conducted a meta-analysis in Transcatheter aortic valve replacement (TAVR) (n=2,498). Dual antiplatelet therapy (DAPT) vs. Single antiplatelet therapy was evaluated on Major or life-threatening bleeding (RR 2.13, 95% CI 1.33-3.40, p=0.016). Compared with single antiplatelet therapy, 3-month and 6-month DAPT following TAVR increased major or life-threatening bleeding.
Synapse has enriched 10 related papers. Consider them for comparative context: